PPBT Profile
Purple Biotech Ltd., a clinical-stage biopharmaceutical company based in Rehovot, Israel, is dedicated to developing innovative therapies designed to address tumor immune evasion and improve treatment outcomes for cancer patients. Founded as Kitov Pharma Ltd., the company rebranded to Purple Biotech Ltd. in December 2020 to reflect its expanded focus on oncology and immuno-oncology. The company’s primary goal is to advance its pipeline of novel cancer therapies through clinical trials and ultimately provide new treatment options for patients with challenging malignancies.
The company's oncology pipeline features several promising therapeutic candidates. CM24, a monoclonal antibody currently in Phase 1b/2 clinical trials, targets carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This therapy is being evaluated as a combination treatment with anti-PD-1 checkpoint inhibitors, aiming to enhance the efficacy of immunotherapy for non-small cell lung cancer and pancreatic cancer. CM24 is designed to disrupt the immune evasion mechanisms of tumors, potentially leading to better clinical outcomes for patients.
In addition, Purple Biotech is developing NT219, a small molecule drug that targets insulin receptor substrate 1 and 2 (IRS1 and IRS2) as well as signal transducer and activator of transcription (STAT). NT219 is currently undergoing Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors, including squamous cell carcinoma of the head and neck. This drug aims to overcome resistance mechanisms and improve the effectiveness of existing cancer treatments by targeting multiple pathways involved in tumor progression.
With a focus on addressing the unmet needs in oncology, Purple Biotech Ltd. is committed to advancing its clinical programs and exploring new avenues in cancer treatment. The company’s innovative approaches to overcoming tumor immune evasion and targeting critical pathways in cancer biology position it as a significant player in the biopharmaceutical industry, dedicated to improving patient outcomes and advancing the field of cancer therapy.
|
